# Hims subscribers in Q1

in Q1 2026

Updated: May 8, 2026

Category: Companies

Tags: KPIs

HTML: /markets/companies/kpis/hims-subscribers-in-q1/

## Short Answer

**Key takeaway.** Both the **model** and the **market** overwhelmingly agree that Hims subscribers in Q1 2026 will be Above 2.4 million, with only minor residual uncertainty.

## Key Claims (January 2026)

**- - Q1 2026 revenue guidance implies 2.41M to 2.51M subscribers.** - Implied subscriber count for Q1 2026 falls below the 2.6M threshold.
- FDA's proposed curbs on weight-loss drugs are a key near-term catalyst.
- Strategic product initiatives are expected to drive Q1 2026 subscriber growth.
- A Novo Nordisk deal and Eucalyptus acquisition appear as bullish upsides for 2026.
- An FDA expert panel for certain peptides was announced April 16.

### Why This Matters (GEO)

- AI agents extract claims, not arguments.
- Improves citation probability in summaries and answer cards.
- Enables fact stitching across multiple sources.

## Executive Verdict

**Key takeaway.** **Model**'s **97.5%** is 1.5pp below 99c **market**, as Q1 2026 guidance implies subscribers below 2.6 million.

### Who Wins and Why

| Outcome | Market | Model | Why |
| --- | --- | --- | --- |
| Above 2.6 million | 27.0% | 10.2% | Research does not highlight strong supporting evidence. |
| Above 2.65 million | 17.0% | 6.1% | Research does not highlight strong supporting evidence. |
| Above 2.55 million | 79.0% | 50.5% | Research does not highlight strong supporting evidence. |

## Model vs Market

| Outcome | Market Probability | Octagon Model Probability |
| --- | --- | --- |
| Above 2.6 million | 27.0% | 10.2% |
| Above 2.65 million | 17.0% | 6.1% |
| Above 2.55 million | 79.0% | 50.5% |
| Above 2.7 million | 7.0% | 2.4% |
| Above 2.4 million | 99.0% | 97.5% |
| Above 2.8 million | 1.0% | 0.2% |
| Above 2.75 million | 1.0% | 0.4% |
| Above 2.45 million | 99.0% | 97.2% |
| Above 2.5 million | 0.0% | 57.4% |

- Expiration: June 10, 2026

## Market Behavior & Price Dynamics

This prediction market has shown a consistent and strong upward trend, opening at a high probability of 91.0% and climbing to its current price of 99.0%. The most significant movement was the jump from 92.0% to 99.0% around May 7. The high starting price suggests that traders had already factored in the year-end 2025 subscriber count of 2.511 million and the company's Q1 revenue guidance. For the market to resolve "Yes," the company needs to have added at least 89,000 net new subscribers. The initial high probability indicates the market believed this growth target was highly achievable based on available financial projections.

The subsequent rise to 99.0% indicates that market conviction has solidified to the point of near certainty. While the provided context does not specify a singular event causing this final spike, it reflects an overwhelming consensus that the subscriber numbers will exceed the 2.6 million threshold. The total trading volume is low at 51 contracts, with the sample data points showing zero volume, which suggests that price movements may be driven by a small number of participants with high conviction rather than broad market activity.

The chart suggests extremely bullish market sentiment regarding Hims & Hers' Q1 subscriber growth. An initial support level was established around the 91.0% mark, with the price never dipping below this point. The current price of 99.0% is acting as a strong resistance level, representing the peak of market confidence. The price action implies that traders see the "Yes" resolution as a foregone conclusion.

## Significant Price Movements

#### 📉 May 08, 2026: 16.0pp drop

Price decreased from 43.0% to 27.0%

**Outcome:** Above 2.6 million

**What happened:** The primary driver of the prediction market price drop was the intensifying competition for GLP-1 users following Amazon Pharmacy's expansion of same-day access to Ozempic [[^]](https://stocktwits.com/news-articles/markets/equity/hims-stock-slides-amazon-ozempic-glp1-ahead-of-earnings/cZX23LbReQx)[[^]](https://www.investing.com/analysis/amazon-takes-a-bite-out-of-hims-what-its-glp1-entrance-means-200679302). This development directly impacts Hims' core growth area and caused Hims' stock to slip, signaling a significant competitive threat to subscriber acquisition and retention [[^]](https://stocktwits.com/news-articles/markets/equity/hims-stock-slides-amazon-ozempic-glp1-ahead-of-earnings/cZX23LbReQx). The news was reported and discussed across various platforms, including Stocktwits, an online social trading community [[^]](https://stocktwits.com/news-articles/markets/equity/hims-stock-slides-amazon-ozempic-glp1-ahead-of-earnings/cZX23LbReQx). Social media, in this instance, served as a channel for information dissemination and market reaction to a traditional news event rather than being the primary originator of the driver.

#### 📈 April 26, 2026: 49.0pp spike

Price increased from 35.0% to 84.0%

**Outcome:** Above 2.6 million

**What happened:** The primary driver of the 49.0 percentage point spike in the "Hims subscribers in Q1" prediction market on April 26, 2026, was a significant preceding rally in Hims & Hers' stock price [[^]](https://rollingout.com/2026/04/21/hims-hers-stock-soars-49-5-things-known/)[[^]](https://tradesoftheday.com/2026/04/20/up-48-in-5-days-this-stock-is-soaring-and-could-be-headed-higher/). The stock surged ~49% in the week of April 15-21, 2026, driven by optimism surrounding the FDA's peptide review, a Novo settlement, and increased weight-loss advertising [[^]](https://rollingout.com/2026/04/21/hims-hers-stock-soars-49-5-things-known/)[[^]](https://www.ibtimes.com/hims-hers-stock-surges-13-fda-peptide-review-optimism-telehealth-momentum-3801397)[[^]](https://www.benzinga.com/news/health-care/26/04/51851887/why-is-hims-hers-stock-soaring-after-fdas-announcment). These traditional news developments, which signaled improved prospects for subscriber growth, likely led the prediction market to adjust expectations for Hims exceeding 2.6 million subscribers [[^]](https://www.subscriptioninsider.com/article-type/news/hims-hers-reaches-2-51m-subscribers-in-fy2025-guides-2026-revenue-to-2-7b-to-2-9b-as-q1-outlook-resets-near-term-expectations)[[^]](https://rollingout.com/2026/04/21/hims-hers-stock-soars-49-5-things-known/)[[^]](https://www.ibtimes.com/hims-hers-stock-surges-13-fda-peptide-review-optimism-telehealth-momentum-3801397). Social media was not a primary driver, as the provided information focuses on traditional news reports about these market-moving catalysts.

## Contract Snapshot

This market resolves to "Yes" if Hims & Hers Health Inc. reports over 2,600,000 subscribers in Q1 2026, and "No" otherwise, with the outcome verified by Fiscal.ai. The market opened on April 16, 2026, and will close by June 10, 2026, at 4:00 PM EDT (or earlier if the event occurs), with payouts projected 30 minutes after closing. Insider trading is prohibited for employees of source agencies and those with material, non-public information.

## Market Discussion

Hims & Hers did not provide a specific subscriber count forecast for Q1 2026, though it expected revenue of $600M–$625M for the quarter [[^]](https://www.sec.gov/Archives/edgar/data/1773751/000177375126000019/hims-20251231x8xkearningsr.htm). Management noted an approximately $65M Q1 2026 revenue headwind from weight-loss shipping cadence changes, affecting revenue recognition but not demand [[^]](https://www.fool.com/earnings/call-transcripts/2026/02/23/hims-hers-hims-earnings-call-transcript/). Public discussion, including a Substack analysis dated Feb 4, 2026, also does not cite an explicit Q1 subscriber forecast, with the company scheduled to announce results on May 11, 2026 [[^]](https://investors.hims.com/news/news-details/2026/Hims--Hers-to-Announce-First-Quarter-2026-Financial-Results-on-May-11-2026/default.aspx).

## Market Data

| Contract | Yes Bid | Yes Ask | Last Price | Volume | Open Interest |
| --- | --- | --- | --- | --- | --- |
| Above 2.4 million | 98% | 100% | 99% | $51 | $51 |
| Above 2.45 million | 92% | 98% | 99% | $25 | $25 |
| Above 2.5 million | 89% | 95% | 0% | $0 | $0 |
| Above 2.55 million | 72% | 79% | 79% | $769.76 | $466.08 |
| Above 2.6 million | 26% | 28% | 27% | $3,822.18 | $2,228.05 |
| Above 2.65 million | 12% | 14% | 17% | $2,986.64 | $2,363.84 |
| Above 2.7 million | 3% | 7% | 7% | $244.94 | $234.94 |
| Above 2.75 million | 0% | 1% | 1% | $50 | $50 |
| Above 2.8 million | 0% | 1% | 1% | $51 | $51 |

## What did Hims & Hers leadership communicate about growth expectations and potential headwinds for Q1 2026 during their Q4 2025 earnings call?

Q1 2026 Revenue Guidance | $600M–$625M (implying 2%–7% year-over-year growth) [[^]](https://www.sec.gov/Archives/edgar/data/1773751/000177375126000019/hims-20251231x8xkearningsr.htm)[[^]](https://finance.yahoo.com/quote/HIMS/earnings/HIMS-Q4-2025-earnings_call-396817.html)[[^]](https://investors.hims.com/news/news-details/2026/Hims--Hers-Health-Inc--Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results/default.aspx) |
Q1 2026 Adjusted EBITDA Guidance | $35M–$55M [[^]](https://www.sec.gov/Archives/edgar/data/1773751/000177375126000019/hims-20251231x8xkearningsr.htm)[[^]](https://finance.yahoo.com/quote/HIMS/earnings/HIMS-Q4-2025-earnings_call-396817.html)[[^]](https://investors.hims.com/news/news-details/2026/Hims--Hers-Health-Inc--Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results/default.aspx) |
Q1 2026 Revenue Headwind | approximately $65M (due to weight-loss shipping changes) [[^]](https://www.investing.com/news/transcripts/earnings-call-transcript-hims--hers-q4-2025-beats-eps-expectations-93CH-4520265)[[^]](https://s27.q4cdn.com/787306631/files/doc_financials/2025/q4/Hims-Hers-Fourth-Quarter-2025-Earnings-Call-Transcript.pdf)[[^]](https://www.youtube.com/watch?v=1UT2UmF1DAQ) |

**Hims & Hers provided specific revenue and EBITDA guidance for Q1 2026**

Hims & Hers provided specific revenue and EBITDA guidance for Q1 2026. The company projects revenue to be between **$600** million and **$625** million, representing an approximate **2%**–**7%** year-over-year growth. Q1 adjusted EBITDA is anticipated to be in the range of **$35** million–**$55** million [[^]](https://www.sec.gov/Archives/edgar/data/1773751/000177375126000019/hims-20251231x8xkearningsr.htm)[[^]](https://finance.yahoo.com/quote/HIMS/earnings/HIMS-Q4-2025-earnings_call-396817.html)[[^]](https://investors.hims.com/news/news-details/2026/Hims--Hers-Health-Inc--Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results/default.aspx). This financial guidance specifically excludes any contribution from the Eucalyptus acquisition and assumes continued access to compounded semaglutide [[^]](https://www.sec.gov/Archives/edgar/data/1773751/000177375126000019/hims-20251231x8xkearningsr.htm)[[^]](https://finance.yahoo.com/quote/HIMS/earnings/HIMS-Q4-2025-earnings_call-396817.html)[[^]](https://investors.hims.com/news/news-details/2026/Hims--Hers-Health-Inc--Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results/default.aspx).

Leadership detailed headwinds influencing Q1 2026 financial performance. Management disclosed an approximate **$65** million revenue headwind for Q1 2026, primarily attributed to changes in weight-loss shipping cadences following the transition to 503A fulfillment [[^]](https://www.investing.com/news/transcripts/earnings-call-transcript-hims--hers-q4-2025-beats-eps-expectations-93CH-4520265)[[^]](https://s27.q4cdn.com/787306631/files/doc_financials/2025/q4/Hims-Hers-Fourth-Quarter-2025-Earnings-Call-Transcript.pdf)[[^]](https://www.youtube.com/watch?v=1UT2UmF1DAQ). They clarified that this headwind impacts the timing of revenue recognition rather than reflecting a change in underlying customer demand or engagement [[^]](https://www.investing.com/news/transcripts/earnings-call-transcript-hims--hers-q4-2025-beats-eps-expectations-93CH-4520265)[[^]](https://s27.q4cdn.com/787306631/files/doc_financials/2025/q4/Hims-Hers-Fourth-Quarter-2025-Earnings-Call-Transcript.pdf)[[^]](https://www.youtube.com/watch?v=1UT2UmF1DAQ). Additionally, the company cited investment in a Super Bowl commercial as an expected factor that would add pressure to EBITDA in the first quarter [[^]](https://www.investing.com/news/transcripts/earnings-call-transcript-hims--hers-q4-2025-beats-eps-expectations-93CH-4520265)[[^]](https://s27.q4cdn.com/787306631/files/doc_financials/2025/q4/Hims-Hers-Fourth-Quarter-2025-Earnings-Call-Transcript.pdf)[[^]](https://www.youtube.com/watch?v=1UT2UmF1DAQ).

Management did not provide specific Q1 subscriber targets. The specific KPI for "Hims subscribers in Q1," as often used by prediction markets, was not presented as a numerical Q1 2026 subscriber target in the reviewed Q4 2025 earnings call materials [[^]](https://www.investing.com/news/transcripts/earnings-call-transcript-hims--hers-q4-2025-beats-eps-expectations-93CH-4520265)[[^]](https://finance.yahoo.com/quote/HIMS/earnings/HIMS-Q4-2025-earnings_call-396817.html). Instead, management chose to focus on providing revenue and EBITDA ranges, complemented by qualitative discussions about growth engines and category durability [[^]](https://www.investing.com/news/transcripts/earnings-call-transcript-hims--hers-q4-2025-beats-eps-expectations-93CH-4520265)[[^]](https://finance.yahoo.com/quote/HIMS/earnings/HIMS-Q4-2025-earnings_call-396817.html).

## How did Hims & Hers' subscriber growth and customer acquisition costs in recent quarters compare to its main competitor, Ro (Roman)?

Hims & Hers Subscribers | Approximately 2.5 million by Q4 2025 [[^]](https://www.sec.gov/Archives/edgar/data/1773751/000177375126000019/finalq42025shareholderle.htm) |
Hims & Hers Q-o-Q Subscriber Increase | 40,000 [[^]](https://www.sec.gov/Archives/edgar/data/1773751/000177375126000019/finalq42025shareholderle.htm) |
Hims & Hers Estimated 2023 CAC | Approximately $784.70 [[^]](https://www.thehealthcarebreakdown.com/p/the-healthcare-breakdown-no-043-breaking)[[^]](https://www.ainvest.com/news/hims-study-sustainable-growth-evolving-unit-economics-2510/) |

**Hims & Hers achieved consistent and substantial subscriber growth through late 2025**

Hims & Hers achieved consistent and substantial subscriber growth through late 2025. The company reached approximately 2.5 million subscribers by the fourth quarter of 2025, representing a quarter-over-quarter increase of 40,000 and a year-over-year increase of 282,000 [[^]](https://www.sec.gov/Archives/edgar/data/1773751/000177375126000019/finalq42025shareholderle.htm). In the third quarter of 2025, Hims & Hers reported nearly 2.5 million subscribers, indicating a **21%** year-over-year growth rate and supporting continued high-teens to low-**20%** year-over-year expansion to reach this scale [[^]](https://www.sec.gov/Archives/edgar/data/1773751/000177375126000019/finalq42025shareholderle.htm)[[^]](https://investors.hims.com/files/doc_financials/2025/q3/Hims-and-Hers_Q3-2025-Shareholder-Letter_Final.pdf).

Directly comparing customer acquisition costs between competitors proves challenging due to data limitations. A precise, quarterly comparison of customer acquisition costs (CAC) between Hims & Hers and its main competitor, Ro (Roman), is not feasible given the insufficient available data [[^]](https://www.thehealthcarebreakdown.com/p/the-healthcare-breakdown-no-043-breaking). The existing CAC figures for Hims & Hers are third-party estimates from various analyses utilizing different methodologies, such as approximately **$784.70** or **$929** for 2023 [[^]](https://www.thehealthcarebreakdown.com/p/the-healthcare-breakdown-no-043-breaking)[[^]](https://www.ainvest.com/news/hims-study-sustainable-growth-evolving-unit-economics-2510/). Furthermore, specific quarterly CAC or subscriber performance metrics for Ro were not found in the provided research [[^]](https://sacra.com/research/ro)[[^]](https://sacra.com/c/ro).

## Based on Hims & Hers' official Q1 2026 revenue guidance ($600M-$625M), what is the implied subscriber count given historical revenue per subscriber trends?

Q1 2026 Revenue Guidance | $600 million to $625 million [[^]](https://ca.investing.com/news/company-news/hims--hers-health-inc-hims-q4-2025-earnings-call-highlights-record-growth-and-strategic--4473617) |
Implied Q1 2026 Subscribers | 2.41 million to 2.51 million [[^]](https://ca.investing.com/news/company-news/hims--hers-health-inc-hims-q4-2025-earnings-call-highlights-record-growth-and-strategic--4473617) |
Q4 2025 Monthly ARPU | $83 [[^]](https://ca.investing.com/news/company-news/hims--hers-health-inc-hims-q4-2025-earnings-call-highlights-record-growth-and-strategic--4473617) |

**Implied subscriber count for Q1 2026 estimated between 2.41 and 2.51 million**

Implied subscriber count for Q1 2026 estimated between 2.41 and 2.51 million. This estimate is based on Hims & Hers' official Q1 2026 revenue guidance, which ranges from **$600** million to **$625** million. By utilizing the company's Monthly Revenue per Average Subscriber (ARPU) of **$83,** as reported for Q4 2025 [[^]](https://ca.investing.com/news/company-news/hims--hers-health-inc-hims-q4-2025-earnings-call-highlights-record-growth-and-strategic--4473617), the implied subscriber count is projected to fall approximately between 2.41 million and 2.51 million.

ARPU has shown consistent stability across recent quarters. The company's ARPU was **$80** in Q3 2025 and increased slightly to **$83** in Q4 2025 [[^]](https://ca.investing.com/news/company-news/hims--hers-health-inc-hims-q4-2025-earnings-call-highlights-record-growth-and-strategic--4473617)[[^]](https://seekingalpha.com/article/4857644-hims-and-hers-capitalizing-on-robust-subscriberarpu-growth-upgraded-buy-rating). For contextual reference, Hims & Hers reported over 2.5 million subscribers at the close of 2025 [[^]](https://www.morningstar.com/news/business-wire/20260223564900/hims-hers-health-inc-reports-fourth-quarter-and-full-year-2025-financial-results)[[^]](https://ca.investing.com/news/company-news/hims--hers-health-inc-hims-q4-2025-earnings-call-highlights-record-growth-and-strategic--4473617). In Q1 2025, the company had 2.4 million subscribers with a monthly online revenue per average subscriber of **$84** [[^]](https://mlq.ai/research/hims-hers-health-deep-dive/)[[^]](https://www.stocktitan.net/news/HIMS/hims-hers-health-inc-reports-first-quarter-2025-financial-3y0fdmfgb0c7.html), further indicating a relatively stable trend in revenue per subscriber.

Calculation confirms specific subscriber range for Q1 2026. Applying the Q4 2025 ARPU of **$83** [[^]](https://ca.investing.com/news/company-news/hims--hers-health-inc-hims-q4-2025-earnings-call-highlights-record-growth-and-strategic--4473617) to the Q1 2026 revenue guidance requires converting the quarterly revenue to average monthly figures. The **$600** million to **$625** million quarterly guidance translates to an average monthly revenue between **$200** million and approximately **$208.33** million. Dividing these monthly revenue figures by the **$83** ARPU [[^]](https://ca.investing.com/news/company-news/hims--hers-health-inc-hims-q4-2025-earnings-call-highlights-record-growth-and-strategic--4473617) suggests an implied subscriber count ranging from approximately 2,409,639 to 2,510,040 subscribers for Q1 2026.

## What are the most reliable public data sources for tracking Hims & Hers' customer retention and churn rates leading up to the Q1 2026 report?

Q1 2026 Results Report Date | May 11, 2026 [[^]](https://investors.hims.com/news/news-details/2026/Hims--Hers-to-Announce-First-Quarter-2026-Financial-Results-on-May-11-2026/default.aspx) |
Primary Data Sources | Investor Relations site and SEC filings [[^]](https://investors.hims.com/overview/default.aspx)[[^]](https://www.sec.gov/Archives/edgar/data/1773751/000177375126000019/hims-20251231x8xkearningsr.htm)[[^]](https://www.sec.gov/Archives/edgar/data/1773751/000177375126000019/finalq42025shareholderle.htm) |
Retention Indicators Location | Key Business Metrics in shareholder letters [[^]](https://www.sec.gov/Archives/edgar/data/1773751/000177375126000019/hims-20251231x8xkearningsr.htm)[[^]](https://s27.q4cdn.com/787306631/files/doc_financials/2025/q1/Hims-and-Hers_Q1-2025-Shareholder-Letter_Final.pdf)[[^]](https://www.sec.gov/Archives/edgar/data/1773751/000177375126000019/finalq42025shareholderle.htm) |

**Hims & Hers' official sources provide Q1 2026 retention data**

Hims & Hers' official sources provide Q1 2026 retention data. The most reliable public data sources for tracking Hims & Hers' customer retention and churn rates leading up to the Q1 2026 report are the company's Investor Relations site and its SEC filings [[^]](https://investors.hims.com/overview/default.aspx)[[^]](https://www.sec.gov/Archives/edgar/data/1773751/000177375126000019/hims-20251231x8xkearningsr.htm)[[^]](https://www.sec.gov/Archives/edgar/data/1773751/000177375126000019/finalq42025shareholderle.htm). The company is scheduled to report its first-quarter 2026 financial results after **market** close on May 11, 2026 [[^]](https://investors.hims.com/news/news-details/2026/Hims--Hers-to-Announce-First-Quarter-2026-Financial-Results-on-May-11-2026/default.aspx). These primary sources, which include investors.hims.com and SEC-hosted documents, offer essential materials such as quarterly shareholder letters and SEC filings like 10-Q, 8-K, and earnings releases [[^]](https://investors.hims.com/overview/default.aspx)[[^]](https://www.sec.gov/Archives/edgar/data/1773751/000177375126000019/hims-20251231x8xkearningsr.htm)[[^]](https://www.sec.gov/Archives/edgar/data/1773751/000177375126000019/finalq42025shareholderle.htm)[[^]](https://investors.hims.com/financials/sec-filings/default.aspx).

Key business metrics reveal retention insights despite no explicit churn. While explicit "churn rate" labels may not always be used, retention and churn indicators are typically embedded within "Key Business Metrics" and related definitions found in shareholder letters [[^]](https://www.sec.gov/Archives/edgar/data/1773751/000177375126000019/hims-20251231x8xkearningsr.htm)[[^]](https://s27.q4cdn.com/787306631/files/doc_financials/2025/q1/Hims-and-Hers_Q1-2025-Shareholder-Letter_Final.pdf)[[^]](https://www.sec.gov/Archives/edgar/data/1773751/000177375126000019/finalq42025shareholderle.htm). For instance, a Q1 2025 shareholder letter included narrative on retention and "online revenue retention" footnotes, while the Q4/FY2025 earnings package referenced subscriber counts and "monthly online revenue per average subscriber" [[^]](https://www.sec.gov/Archives/edgar/data/1773751/000177375126000019/hims-20251231x8xkearningsr.htm)[[^]](https://www.sec.gov/Archives/edgar/data/1773751/000177375126000019/finalq42025shareholderle.htm)[[^]](https://s27.q4cdn.com/787306631/files/doc_financials/2025/q1/Hims-and-Hers_Q1-2025-Shareholder-Letter_Final.pdf). The "subscriber count (end of period)" is consistently disclosed as a key performance indicator in earnings materials [[^]](https://www.sec.gov/Archives/edgar/data/1773751/000177375126000019/hims-20251231x8xkearningsr.htm)[[^]](https://www.sec.gov/Archives/edgar/data/1773751/000177375126000019/finalq42025shareholderle.htm)[[^]](https://s27.q4cdn.com/787306631/files/doc_financials/2025/q1/Hims-and-Hers_Q1-2025-Shareholder-Letter_Final.pdf).

## What specific product launches or marketing initiatives from late 2025 and Q1 2026 are expected to be the primary drivers of Hims & Hers' subscriber growth?

Labs Launch Date | Nov 13, 2025 [[^]](https://news.hims.com/newsroom/introducing-labs-by-hims-hers)[[^]](https://finance.yahoo.com/quote/HIMS/earnings/HIMS-Q4-2025-earnings_call-396817.html) |
Men's Health New Category Launch (Low Testosterone) | Sep 2025 [[^]](https://www.businesswire.com/news/home/20250910502249/en/Hims-Launches-New-Category-in-Mens-Health-with-Exclusive-Branded-Oral-Testosterone-and-Expanded-Personalized-Treatments)[[^]](https://stockinsights.ai/us/HIMS/earnings-transcript/fy25-q4-2560) |
Super Bowl Commercial Length | 60 seconds [[^]](https://stockinsights.ai/us/HIMS/earnings-transcript/fy25-q4-2560) |

**Hims & Hers anticipates subscriber growth driven by strategic product initiatives**

Hims & Hers anticipates subscriber growth driven by strategic product initiatives. The company plans to sustain growth into late 2025 and Q1 2026 through ongoing weight loss acquisition efforts, the introduction of the Labs platform, and continued expansion in men's health [[^]](https://www.fool.com/earnings/call-transcripts/2026/02/23/hims-hers-hims-earnings-call-transcript/)[[^]](https://news.hims.com/newsroom/introducing-labs-by-hims-hers)[[^]](https://finance.yahoo.com/quote/HIMS/earnings/HIMS-Q4-2025-earnings_call-396817.html)[[^]](https://www.businesswire.com/news/home/20250910502249/en/Hims-Launches-New-Category-in-Mens-Health-with-Exclusive-Branded-Oral-Testosterone-and-Expanded-Personalized-Treatments)[[^]](https://stockinsights.ai/us/HIMS/earnings-transcript/fy25-q4-2560). The Labs initiative, launched on November 13, 2025, aims to attract new subscribers by engaging consumers in new specialties via proactive diagnostics and personalized treatment options [[^]](https://news.hims.com/newsroom/introducing-labs-by-hims-hers)[[^]](https://finance.yahoo.com/quote/HIMS/earnings/HIMS-Q4-2025-earnings_call-396817.html). Furthermore, the expansion in men's health, which included a new low testosterone category introduced in September 2025, is expected to be a key driver of subscriber growth throughout 2026 [[^]](https://www.businesswire.com/news/home/20250910502249/en/Hims-Launches-New-Category-in-Mens-Health-with-Exclusive-Branded-Oral-Testosterone-and-Expanded-Personalized-Treatments)[[^]](https://stockinsights.ai/us/HIMS/earnings-transcript/fy25-q4-2560).

A major marketing push will significantly contribute to Q1 2026 subscriber acquisition. This includes a national Super Bowl advertising campaign in Q1 2026, featuring a 60-second commercial designed to educate consumers about the platform and contribute to subscriber acquisition [[^]](https://stockinsights.ai/us/HIMS/earnings-transcript/fy25-q4-2560). Management specifically expects strong subscriber growth from its weight loss offering in Q1 2026, reflecting a continued focus on GLP-1 treatments and related marketing [[^]](https://www.fool.com/earnings/call-transcripts/2026/02/23/hims-hers-hims-earnings-call-transcript/). Additionally, international expansion commenced in December 2025 with the launch of a weight-loss and Hers platform in the UK, which is anticipated to indirectly influence overall company subscriber growth in Q1 2026 [[^]](https://news.hims.com/newsroom/hims-hers-brings-comprehensive-weight-loss-programme-to-the-uk).

## What Could Change the Odds

**Key takeaway.** The proposed new curbs by the FDA on mass compounding of branded weight-loss drugs are framed as the single biggest near-term catalyst for Hims & Hers [[^]](https://www.tikr.com/blog/hims-hers-is-down-7-after-fda-proposes-new-glp-1-drug-rules-heres-what-investors-should-know).

**Key takeaway.** Bullish upsides for 2026 include a Novo Nordisk deal/distribution, an Eucalyptus acquisition closing expected mid-2026, and an FDA expert panel for certain peptides announced April 16 [[^]](https://www.tikr.com/blog/novo-deal-eucalyptus-acquisition-fda-peptides-three-catalysts-reshaping-hims-hers-in-2026).

**Hims & Hers will announce its first-quarter 2026 financial results after market close on Monday, May 11, 2026 [[^]](https://investors.hims.com/news/news-details/2026/Hims--Hers-to-Announce-First-Quarter-2026-Financial-Results-on-May-11-2026/default.aspx).** A dedicated prediction-**market** contract's resolution for Q1 2026 subscribers is 'Yes' if Hims & Hers reports Above 2,600,000 subscribers [[^]](https://kalshi.com/markets/kxhims/hims-kpi/kxhims-26maysubs). In Hims & Hers' FY2025 results, subscribers (end of period) were reported as 2,511 thousand, and the company discussed growth to over 2.5M subscribers [[^]](https://www.sec.gov/Archives/edgar/data/1773751/000177375126000019/hims-20251231x8xkearningsr.htm).

## Key Dates & Catalysts

- **Expiration:** June 10, 2026
- **Closes:** June 10, 2026

## Decision-Flipping Events

- The proposed new curbs by the FDA on mass compounding of branded weight-loss drugs are framed as the single biggest near-term catalyst for Hims & Hers [^] .
- Bullish upsides for 2026 include a Novo Nordisk deal/distribution, an Eucalyptus acquisition closing expected mid-2026, and an FDA expert panel for certain peptides announced April 16 [^] .
- Hims & Hers will announce its first-quarter 2026 financial results after **market** close on Monday, May 11, 2026 [^] .
- A dedicated prediction-**market** contract's resolution for Q1 2026 subscribers is 'Yes' if Hims & Hers reports Above 2,600,000 subscribers [^] .

## Related Research Reports

- [When will Apple announce foldable iPhone?](/markets/companies/product-launches/when-will-apple-announce-foldable-iphone/)
- [Courts consider Apple a monopoly?](/markets/companies/courts-consider-apple-a-monopoly/)
- [Jamie Dimon leaves JPMorgan Chase?](/markets/companies/ceos/jamie-dimon-leaves-jpmorgan-chase/)
- [When will Tim Cook leave Apple?](/markets/companies/ceos/when-will-tim-cook-leave-apple/)

## Historical Resolutions

No historical resolution data available for this series.

## Disclaimer

This content is for informational and educational purposes only and does not constitute financial, investment, legal, or trading advice.
Prediction markets involve risk of loss. Past performance does not guarantee future results.
We are not affiliated with Kalshi or any prediction market platform. Market data may be delayed or incomplete.

### Data Sources & Model Transparency

**Data Sources:** Octagon Deep Research aggregates information from multiple sources including news, filings, and market data.

**Freshness:** Analysis is generated periodically and may not reflect the latest developments. Verify critical information from primary sources.

## Attribution Policy

When quoting, summarizing, or reproducing Octagon AI content, attribute it to Octagon AI and link to the Octagon source URL: https://octagonai.co/markets/companies/kpis/hims-subscribers-in-q1
If a specific page was used, cite that page rather than only the site homepage.